Document Detail


Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
MedLine Citation:
PMID:  21824629     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Parkinson's disease (PD) is one of the most common disabling neurodegenerative diseases. Although several therapeutic approaches are available, there are two major unresolved issues: the lack of proved neuroprotective therapy and the treatment of L-dopa-induced motor complications. In the brain, 90% of the tryptophan is metabolized in the kynurenine pathway. Some of the intermediates, such as quinolinic acid and 3-hydroxy kynurenine, are neurotoxic, while others, such as kynurenic acid, are putative intrinsic neuroprotective compounds, mainly by acting as endogenous antagonists of ionotropic excitatory amino acid receptors. Alterations in the kynurenine pathway have been demonstrated in PD. Preclinical data suggest that intervention in the kynurenine pathway may result in neuroprotection and may alleviate L-dopa-induced dyskinesia. There are two alternative approaches for such intervention: the use of kynurenic acid analogues or pro-drugs, or modulation of the activities of the intrinsic enzymes of the pathway.
Authors:
Nikoletta Szabó; Zsigmond Tamás Kincses; József Toldi; Laszló Vécsei
Related Documents :
22180549 - Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
649259 - Solid-phase peptide synthesis using mild base cleavage of n alpha-fluorenylmethyloxycar...
12089559 - A trna aminoacylation system for non-natural amino acids based on a programmable ribozyme.
2291439 - Application of immobilized growing cells.
8738649 - Solid-phase synthesis of h- and methylphosphonopeptides.
3679669 - Mild, orthogonal solid-phase peptide synthesis: use of n alpha-dithiasuccinoyl (dts) am...
17289839 - Characterization of the ph of folate receptor-containing endosomes and the rate of hydr...
3376919 - Chewing gum is as effective as food in stimulating cephalic phase gastric secretion.
21139129 - A simple method of supplementation of omega-3 polyunsaturated fatty acids: use of forti...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2011-08-06
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  310     ISSN:  1878-5883     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-17     Completed Date:  2012-02-16     Revised Date:  2012-04-16    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  256-60     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Affiliation:
Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiparkinson Agents / adverse effects
Humans
Kynurenine / metabolism
Levodopa / adverse effects
Parkinson Disease / drug therapy,  metabolism*
Tryptophan / metabolism*
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Levodopa; 343-65-7/Kynurenine; 73-22-3/Tryptophan
Comments/Corrections
Comment In:
J Neurol Sci. 2012 Apr 15;315(1-2):180; author reply 181-2   [PMID:  22169632 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduced cerebellar left hemisphere and vermal volume in adults with PTSD from a community sample.
Next Document:  Outcomes of total arch replacement with stepwise distal anastomosis technique and modified perfusion...